Produto adicionado correctamente ao carrinho.

discount label
H-AVEEVSLRK-OH
Ver 3D

Biosynth logo

H-AVEEVSLRK-OH

Ref. 3D-PP48716

1mg
217,00 €
10mg
253,00 €
100mg
455,00 €
Entrega estimada em Estados Unidos, Quinta-feira 2 de Janeiro de 2025

Informação sobre produto

Nome:
H-AVEEVSLRK-OH
Descrição:

Peptide H-AVEEVSLRK-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-AVEEVSLRK-OH include the following: Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia Y Shi, Y Xue, C Wang, L Yu - Hematology, 2022 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/16078454.2022.2067939 Monitoraggio delle risposte T-cellulari specifiche contro la proteina NPM1 mutata in pazienti con leucemia acuta mieloide con mutazione di NPM1: correlazione con l' S TEDDE - 2017 - morethesis.unimore.ithttps://morethesis.unimore.it/theses/available/etd-09192017-142541/ Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin R Narayan, N Olsson , LE Wagar , BC Medeiros - PLoS , 2019 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0219547 HLA class I genotype Is associated with relapse risk after allogeneic stem cell transplantation for NPM1-mutated acute myeloid leukemia R Narayan, A Niroula , T Wang, M Kuxhausen - and cellular therapy, 2023 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2666636723012046 Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation L Chin, CYG Wong, H Gill - International Journal of Molecular Sciences, 2023 - mdpi.comhttps://www.mdpi.com/1422-0067/24/4/3161 Genetic alterations and their clinical implications in acute myeloid leukemia HA Hou , WC Chou, HF Tien - Myeloid leukemia: basic , 2011 - books.google.comhttps://books.google.com/books?hl=en&lr=&id=juecDwAAQBAJ&oi=fnd&pg=PA163&dq=(%22AVEEVSLRK%22+OR+%22H-AVEEVSLRK-OH%22)+AND+peptide&ots=r9rz8UDCP_&sig=Ot69NUaRRqDef_i9qBaG1JUBscU Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia HA Hou - Pathogenesis and Treatment of Leukemia, 2023 - Springerhttps://link.springer.com/chapter/10.1007/978-981-99-3810-0_5 Human leukocyte antigens and adult acute myeloid leukemia: A first report from Lebanon H El Achkar, H Tamim , AK El Karaaoui, P Fermanian - Human Gene, 2023 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2773044123000189 Immunotherapy Targeting Mutant Nucleophosmin-1 on Acute Myeloid Leukemia G Koutsoumpli, DI van der Lee, NC Groenland - Blood, 2022 - ashpublications.orghttps://ashpublications.org/blood/article/140/Supplement%201/10243/489588 Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia F Forghieri, G Riva, I Lagreca, P Barozzi - International Journal of , 2021 - mdpi.comhttps://www.mdpi.com/1422-0067/22/17/9159 Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia F Forghieri, G Riva, I Lagreca, P Barozzi, D Vallerini - Oncotarget, 2019 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368236/ The Role and Immunogenicity of CBFA2T3-GLIS2 in Pediatric Acute Megakaryoblastic Leukemia EA Garfinkle - 2022 - search.proquest.comhttps://search.proquest.com/openview/bfa7248d577f93fabb52207e6cfa79f4/1?pq-origsite=gscholar&cbl=18750&diss=y An HLA-A* 11: 01-binding neoantigen from mutated NPM1 as target for TCR gene therapy in AML DI van der Lee, G Koutsoumpli, RM Reijmers - Cancers, 2021 - mdpi.comhttps://www.mdpi.com/2072-6694/13/21/5390 Mutated Regions of Nucleophosmin 1 Elicit CD8+ T-Cell Responses in Patients with Acute Myeloid Leukemia A Sun, Z Cheng, G Chen, X Yang, W Depei - Blood, 2014 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119740403 Leucemia Acuta Mieloide con mutazione del gene della nucleofosmina (NPM1): dalle caratteristiche immunoistochimiche alle risposte immunologiche A PAOLINI - 2019 - morethesis.unimore.ithttps://morethesis.unimore.it/theses/available/etd-12142018-102509/ Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules A Liso , D Colau, R Benmaamar, A De Groot , W Martin - Leukemia, 2008 - nature.comhttps://www.nature.com/articles/2404887

Aviso:
Os nossos productos estão destinados exclusivamente para uso em laboratório. Para qualquer outra aplicação, por favor entre em contacto.
Marca:
Biosynth
Armazenamento a longo prazo:
Notas:

Propriedades químicas

MDL:
Ponto de fusão:
Ponto de ebulição:
Ponto de inflamação:
Densidade:
Concentração:
EINECS:
Merck:
Código HS:

Informação sobre riscos

Número ONU:
EQ:
Classe:
Frases H:
Frases P:
Proibido de voar:
Informação sobre riscos:
Grupo de Embalagem:
LQ:

Consulta técnica sobre: 3D-PP48716 H-AVEEVSLRK-OH

Por favor, utilize o carrinho para solicitar um orçamento ou uma encomenda

Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.

* Campos obrigatórios
Bem-vindo à CymitQuimica!Usamos cookies para melhorar sua visita. Não incluímos publicidade.

Consulte a nossa Política de Cookies para mais detalhes ou ajuste suas preferências em "Configurar".